Universal Health Services (UHS) Up 11.4% Since Last Earnings Report: Can It Continue?

Universal Health Services (UHS) reported robust Q2 2025 results, with adjusted EPS of $5.35, a 24.1% year-over-year increase and 10.3% beat, and net revenues up 9.6% year-over-year to $4.3 billion, driven by strong acute care and behavioral health admissions. Following this performance, management raised its full-year 2025 guidance across net revenues, adjusted EBITDA, and EPS to a range of $20-$21. UHS shares have gained 11.4% since the earnings report, outperforming the S&P 500, with analyst estimates trending upward, though the stock currently holds a Zacks Rank #3 (Hold) expecting an in-line return.

Analysis

Universal Health Services (UHS) delivered a robust second-quarter 2025 performance, exceeding consensus estimates with a 24.1% year-over-year increase in adjusted EPS to $5.35 and a 9.6% rise in net revenues to $4.3 billion. This growth was driven by solid volume increases across its core segments, with same-facility adjusted admissions rising 2% in Acute Care and 0.4% in Behavioral Health. The strong operational results prompted management to raise its full-year 2025 guidance for revenue, adjusted EBITDA, and EPS, with the latter now projected in the $20-$21 range. Despite this positive top-line and earnings momentum, which has propelled the stock up 11.4% since the report, there are underlying factors requiring scrutiny. Total operating costs escalated 9% year-over-year, and more notably, cash flows from operations declined 19.2% from the prior-year period. While the company continues to return capital to shareholders, repurchasing $150.8 million in shares, the combination of strong earnings, a 'Hold' rating from Zacks, and a declining cash flow metric presents a mixed but fundamentally positive picture.

Key Decisions for Investors

• Given the strong earnings beat, raised full-year guidance, and ongoing share repurchases, investors may view the fundamental picture as supportive of the recent stock appreciation.
• It is critical to monitor the 19.2% year-over-year decline in operating cash flow and the 9% rise in operating costs, as sustained pressure in these areas could challenge future profitability and valuation.
• Considering the stock's Zacks #3 (Hold) rating and its 'C' for Momentum, investors might consider the possibility of a near-term pullback after the 11.4% run-up and evaluate its performance relative to higher-rated peers like Tenet Healthcare.